– Cendakimab, a high-affinity monoclonal antibody against IL-13, significantly reduces dysphagia days in EoE patients.
– Achieves histologic response with marked reduction in esophageal eosinophil infiltration.
– Demonstrates improvement in endoscopic severity scores sustained up to 48 weeks.
– Adverse events are common but not dose-limiting, supporting an acceptable safety profile.
Study Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
